Campuzano RR

Language: Spanish
References: 19
Page: 140-147
PDF size: 93.98 Kb.

ABSTRACT

Without any kind of doubt, one of the most difficult decisions to be taken at present is the purpose of beginning the Replacement Hormonal Therapy (RHT) and when starting it. At the beginning of the decade of the 90’s, a great number of women were being subjected to RHT and the explanation consists of the fact that most of the observational studies had demonstrated that estrogen made cholesterol decrease, and because of that coronary diseases. This may be probably explained through the improvement of lipid profile which affect climacteric, besides the very same benefits on skeleton, genitourinary apparatus and emotional state. During the middle 90’s, two researches changed the prescription of estrogen in a drastic way. These studies were HERS I and HERS II, as well as WHI. In those studies no beneficial effect was demonstrated when employing RHT to improve or treat coronary diseases. It was demonstrated that there was a minimum risk of contracting mammary gland cancer and a higher risk of presenting cardiovascular brain diseases, specially among women who had begun such therapy at late climacteric. The reactions did not last so long, WHI has been criticized a lot due to its design and the study evaluation or assessment. In this study, we make reference to some of the best criticisms which have been analyzed with regard to scientific bases. Such criticisms have made the “pendulum” get back and now even the most radical detractors of RHT have accepted that such a treatment presents a prevailing role in climacteric and when it is consciously employed it has more benefits than risks. Here, we make reference to the therapeutic guides accepted by different institutions at the international level, and we also show some research works that indicate that it is not clear enough whether RHT delays the appearance of atherosclerosis, mainly when it is employed in women being younger than the average female patients who had entered the WHI.

REFERENCES

1. Grady, Rubin, Petitti et al. Review. Hormone Therapy to prevent disease and prolong life en Postmenopausal Women. Ann Inter Medicine 1992; 117: 12: 1016-1037.

2. Mendelsohn ME, Karas RH. Review. Mechanisms of disease: The protective effects of estrogen on the cardiovascular system. NEJM 1999; 340(23): 1801.

3. Skafar DF, Rui XU, Jeffrey RJM, Sower JR. J Clinic Endocrinol Metab 1997; 82(12): 3913-3918.

4. Catherine M et al. A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med 2001; 345(17): 1243-1249.

5. Herrington DM et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 2000; 343(8): 522-529.

6. Friday KE, Dong C, Rhonda U. Fontenot: Conjugated equine estrogen improves glycemic control and blood lipoproteins in postmenopausal women with type 2 diabetes. J Clinic Endocrinol Metab 2001; 86(1): 48-52.

7. Skouby SO. Act commentary: Consequences for HRT following the HERS II WHI reports: The primum non nocere is important, but translation in quo vadis is even more essential. Acta Obstet Gynecol Scand 2002; 81: 793-798.

8. Grady D et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and estrogen/progestin replacement study follow-up (HERS II). JAMA 2002; 288(1): 49-57.

9. Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002; 288(3): 321-333.

10. Skouby SO. Acta commentary: Consequences for HRT following the HERS II WHI reports: The primum non nocere is important, but translation in quo vadis is even more essential. Acta Obstet Gynecol Scand 2002; 81: 793-798.

11. Mosca L et al. Hormone replacement therapy and cardiovascular disease a statement for healthcare professionals from the American Heart Association. Circulation 2001; 104: 499-503.

12. Manson JE, Martin KA. Postmenopausal hormone replacement therapy. N Engl J Med 2001; 345(1): 34-40.

13. Creasman WT, Hoel D, DiSaia PJ. WHI: Now that the dust has settled. Am J Obstet Gynecol 2003; 189: 621-626.

14. Schneider HPG. The view of The International Menopause Society on the Women’s Health Initiative. Climateric 2002; 5(3): 211-216.

15. Lobo RA. View on recent trials and the future of hormonal therapy. Clinical Obstetrics and Ginecology 2004; 47(2): 424-427.

16. Lobo RA. Evaluation of cardiovascular event rates with hormone therapy en healthy early postmenopausal women: Results from 2 large clinical trials. Arch Intern Med 2004; 164: 482-484.

17. Akhrass F et al. Hormone replacement therapy is associated with less coronary atherosclerosis in postmenopausal women. J Clinic Endocrinol and Metab 2003; 88(12): 5611-5614.

18. Martin KA et al. Recommendations for hormone replacement therapy. Uptodate in medicine. Eds Burton Rose Copyright. 2004.

19. Martin KA et al. Estrogens replacement therapy. Benefits and Risks. Uptodate in Medicine. Eds Burton Rose. Copyright 2004.